The IPD-IMGT/HLA Database Submission Tool allows direct submission of sequences to the WHO HLA Nomenclature Committee for Factors of the HLA System. Once accepted the submitted sequence will be stored in the database and appear in the monthly updates published in Tissue Antigens, Human Immunology and the International Journal of Immunogenetics.
Start your submission here
Please read the guidelines below for submitting a new or confirmatory sequence before starting the submission procedure, as you will be asked to confirm you have read them during the submission process.
Conditions for acceptance of new allele sequences.
As emphasized in previous reports and releases from the HLA database, there are required conditions for the acceptance of new sequences for official names. Please read the following conditions carefully before submitting sequences.
- Where a sequence is obtained from cDNA or where PCR products are subcloned prior to sequencing, several clones must have been sequenced.
- Sequencing must always be performed in both directions.
- If direct sequencing of PCR amplified material is performed, products from at least two separate PCR reactions must have been sequenced.
- In individuals who are heterozygous for a locus, where one of the alleles is novel, the novel allele must be sequenced in isolation from the second allele. Thus an allele sequence which is derived using a sequence based typing (SBT) methodology, where both alleles of a heterozygous individual are sequenced together, is insufficient evidence for assignment of an official designation.
- Sequence derived solely from the primers used to amplify an allele must not be included in the sequence that is submitted.
- Where possible, a novel sequence must be confirmed by typing of genomic DNA using a method such as PCR-SSOP or PCR-SSP. Where a new sequence contains either a novel mutation or a previously unseen combination of nucleotides (sequence motif), this must be confirmed by a DNA typing technique. This may require the use of newly designed probes or primers to cover the new mutation; these reagents should also be described.
- An accession number in a databank must have been
obtained. Sequences may be submitted to these databases online
at the following addresses:
- Full length sequences are preferable though not essential; the minimum requirements are exons 2 and 3 for an HLA class I sequence and exon 2 for an HLA class II sequence.
- Where a novel sequence differs only within an intron or other non-coding part of the gene, a full length sequence must be obtained, which covers all coding and non-coding regions. In the absence of a full length genomic sequence from the most closely related allele, it may be required that this also be sequenced and submitted before a name can be assigned to the novel sequence.
- Where possible, a paper in which the new sequence is described should be submitted for publication. Draft publications can be submitted to the database by email or fax (+44 20 7284 8331).
- When HLA typing patients with haematological malignancies it is to essential confirm the presence of any novel alleles in the germline. This is possible by using DNA collected by buccal swab. Sequences derived solely from tumour material, or without sufficient evidence of the additional work to confirm the sequence in the germline will not be considered for nomenclature.
- The complete HLA type for HLA-A, -B, -DRB1 genes must be submitted for the material in which a novel allele has been defined. In addition the sample should have been characterised for the second allele at the locus of interest in a heterozygous individual.
- DNA or other material, preferably cell lines, should, wherever possible, be made available in a publicly accessible repository or alternatively, at least in the originating laboratory. Documentation on this will be maintained by the WHO Nomenclature Committee.
- Submission of a sequence to the Nomenclature Committee must be performed using the online tool available at /imgt/hla/subs/submit.html. Researchers will be expected to complete the following questionnaire relating to the sequence and provide a comparison of their new sequence with known related alleles. If the sequence cannot be submitted using the online web tools researchers should contact IPD-IMGT/HLA directly for details of alternative submission methods.
Although at present it is only a recommendation that full-length sequences of the coding region of novel alleles be submitted it was widely felt that in the future this should become a requirement for submission. Such requirement would remove many of the currently encountered ambiguities in the assignment of names to alleles for which partial sequences have been submitted and should not be burdensome as sequencing techniques have improved substantially since the submission conditions were first devised. In cases where novel mutations or polymorphisms are detected in non-coding regions of the gene, it will be a requirement that full-length sequences be submitted of both the novel allele and its most closely related allele.
It should be noted with some caution that cells from which only partial sequences have been obtained may later be shown to have different or novel alleles when further sequencing is performed. This is of particular importance in cases where partial sequences of what appears to be the same allele have been obtained from several different cells. In such cases, all cells studied have been listed in this report.
Current practice is that official designations will be promptly assigned to newly described alleles in periods between Nomenclature Committee meetings, provided that the submitted data and its accompanying description meet the criteria outlined above. A list of the newly reported alleles is published each month in nomenclature updates in the journals Tissue Antigens, Human Immunology and the International Journal of Immunogenetics. The listing of references to new sequences does not imply priority of publication. The use of numbers or names for alleles, genes or specificities which pre-empt assignment of official designations by the Nomenclature Committee is strongly discouraged.